CRIS Current Research Information System

MANCINI, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.536
AS - Asia 4.495
EU - Europa 2.966
AF - Africa 270
SA - Sud America 200
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.478
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.471
VN - Vietnam 1.542
SG - Singapore 1.158
CN - Cina 909
GB - Regno Unito 667
IT - Italia 504
DE - Germania 393
SE - Svezia 336
HK - Hong Kong 279
FR - Francia 176
NL - Olanda 170
IN - India 163
RU - Federazione Russa 156
BR - Brasile 137
IE - Irlanda 135
UA - Ucraina 132
TG - Togo 88
JP - Giappone 82
ZA - Sudafrica 69
FI - Finlandia 60
KR - Corea 56
EE - Estonia 53
CI - Costa d'Avorio 52
BD - Bangladesh 51
CA - Canada 40
JO - Giordania 40
CH - Svizzera 33
BG - Bulgaria 30
TH - Thailandia 29
NG - Nigeria 25
ID - Indonesia 23
IR - Iran 22
AR - Argentina 21
BE - Belgio 21
IQ - Iraq 20
PL - Polonia 17
TW - Taiwan 17
EC - Ecuador 16
MX - Messico 16
SA - Arabia Saudita 16
TR - Turchia 15
CZ - Repubblica Ceca 14
SC - Seychelles 14
ES - Italia 13
PH - Filippine 13
GR - Grecia 10
PK - Pakistan 10
VE - Venezuela 10
AT - Austria 9
UZ - Uzbekistan 9
AU - Australia 7
LT - Lituania 7
RO - Romania 7
HR - Croazia 6
LB - Libano 6
MA - Marocco 6
MY - Malesia 6
NP - Nepal 6
CL - Cile 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
DZ - Algeria 3
GE - Georgia 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
MD - Moldavia 2
MU - Mauritius 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LY - Libia 1
MM - Myanmar 1
MR - Mauritania 1
Totale 12.470
Salva come PNG Salva come JPEG
Città #
Singapore 842
Southend 576
Ashburn 493
Chandler 469
Ho Chi Minh City 387
Fairfield 349
San Jose 306
Hanoi 303
Hong Kong 263
Wilmington 193
Seattle 191
Houston 171
Woodbridge 170
Dong Ket 160
Beijing 150
Princeton 138
Dublin 135
Cambridge 131
Ann Arbor 122
Bologna 103
Hefei 102
Santa Clara 100
Lomé 88
Boardman 87
Jacksonville 79
Tokyo 67
New York 62
Nanjing 61
Lauterbourg 60
Los Angeles 60
Westminster 58
Abidjan 52
Padova 52
Helsinki 47
Berlin 46
Da Nang 42
Seoul 42
Milan 41
Redmond 40
Frankfurt am Main 39
Amman 35
Council Bluffs 33
San Diego 33
Redondo Beach 32
Haiphong 31
Sofia 30
Medford 29
Shenyang 29
Jinan 28
Bern 27
Buffalo 27
Changsha 24
Saint Petersburg 24
Abeokuta 23
Biên Hòa 22
Ha Long 22
Munich 22
Falkenstein 21
Hebei 21
Turin 21
Brussels 20
Falls Church 20
Dallas 19
Tianjin 19
Nanchang 18
São Paulo 18
Florence 17
Guangzhou 17
London 17
Nuremberg 16
Rome 16
Zhengzhou 16
Bremen 15
Dearborn 15
Jiaxing 15
Phoenix 15
Shanghai 15
Johannesburg 14
Norwalk 14
Toronto 14
Bengaluru 13
Brooklyn 13
Chicago 13
Montreal 13
Mülheim 13
Orem 13
Thái Nguyên 13
Atlanta 12
Jakarta 12
Taizhou 12
Bangkok 11
Can Tho 11
Des Moines 11
Washington 11
Xi'an 11
Baghdad 10
Bắc Ninh 10
Hangzhou 10
Mountain View 10
Ninh Bình 10
Totale 7.973
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 662
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 283
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 275
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 267
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 243
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 231
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 228
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 220
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 213
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 213
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 208
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 197
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 191
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 188
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 187
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 185
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 184
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 183
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 178
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 176
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 176
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 174
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 173
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 173
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 173
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 172
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 172
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
Best practices in chronic myeloid leukemia monitoring and management 167
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 167
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 164
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 164
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 163
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 162
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 161
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 160
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 159
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 158
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 158
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 157
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 157
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 156
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 156
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 154
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 153
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 150
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 149
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 145
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 145
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 145
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 142
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 140
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 138
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 137
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 135
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 135
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 133
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 130
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 128
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 125
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
Systemic mastocytosis: Molecular landscape and implications for treatment 122
Present and future of molecular monitoring in chronic myeloid leukaemia. 119
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 118
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 116
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 111
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 109
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 98
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability 75
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib 2
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 12.672
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.439
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.439
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021304 0 0 0 0 0 0 0 0 0 0 0 304
2021/20221.273 138 25 78 83 117 77 28 87 57 85 250 248
2022/20231.640 185 263 88 197 119 128 59 73 281 41 133 73
2023/2024449 20 79 27 63 37 100 22 29 14 21 16 21
2024/20251.685 47 273 152 118 201 71 137 79 34 216 83 274
2025/20264.509 400 722 303 282 516 208 338 163 951 336 178 112
Totale 12.672